The patent portfolio Lipigon has purchased is made up of drug candidates developed by Lipigon in collaboration with German biotech company Secarna Pharmaceuticals. By inhibiting a blood fat regulating protein, blood fats are broken down, which in turn reduces the levels of harmful blood fats.
“This deal means Lipigon completely takes over the rights and development of the drug candidate Lipisense, which we previously shared with Secarna,” explains Stefan K Nilsson.
Lipigon, which is located at the Umeå Biotech Incubator, develops medicines for lipid-related disorders, i.e. diseases caused by irregularities when fats are processed in the body. Of these the most well-known is cholesterol and the role it plays in the development of cardiovascular disease, but fats can also contribute to various liver diseases, type 2 diabetes and a number of rare so-called ‘orphan drug’ diseases.
With a market base of around 140 million patients worldwide, the potential market value of an effective treatment to combat these types of conditions is estimated at several billion dollars.
“Lipisense is our most advanced project to date. The fact we now own the product candidates, patent applications and have full control over its development makes it easier for us to attract investors and new capital and also gives us an advantage when exploring new business opportunities,” says Stefan K Nilsson.
In October 2019 Lipigon signed a multi-million SEK deal with the listed company CombiGene AB.
“There’s a lot happening right now and new opportunities are emerging all the time. We are in the early stage of raising new capital for the continued development of Lipisense and see that several potential partners and investors are focusing on Umeå. Lipigon has previously been very successful in attracting capital and we are confident this will continue,” says Stefan K Nilsson.
For more information please contact:
Stefan K Nilsson, CEO Lipigon
+46 70-578 17 68
Lipigon are lipid biology experts focusing on developing novel therapeutics for patients with lipid- related disorders. The company is a spin-off from Umeå University, Sweden, based on five decades of lipid research. Our primary focus is orphan lipid disorders and in addition to the ANGPTL antisense program, Lipigon’s pipeline, including a project for gene therapy treatment of lipodystrophy. This program is partnered with Combigene AB (publ). www.lipigon.se.